PGAM1 and non-small cell lung carcinoma: Shen and colleagues identified a novel PGAM1 allosteric inhibitor HKB99 that blocked conformational change of PGAM1 during catalytic process, and demonstrated an excellent impact of HKB99 for improving erlotinib resistance through alterations of multiple signaling pathways in NSCLC (Huang K. et al., 2021).